About Cellares
Cellares is a company based in San Francisco (United States) founded in 2019 by Fabian Gerlinghaus and Omar Kurdi.. Cellares has raised $355 million across 3 funding rounds from investors including Bristol-Myers Squibb, Koch Disruptive Technologies and DFJ Growth. Cellares operates in a competitive market with competitors including 10X Genomics, Mission Bio, LUMICKS, LevitasBio and Rebus Biosystems, among others.
- Headquarter San Francisco, United States
- Founders Fabian Gerlinghaus, Omar Kurdi
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$355 M (USD)
in 3 rounds
-
Latest Funding Round
$255 M (USD), Series C
Aug 23, 2023
-
Investors
Bristol-Myers Squibb
& 8 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Cellares
Cellares has successfully raised a total of $355M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $255 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $255.0M
-
First Round
First Round
(01 Aug 2019)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2023 | Amount | Series C - Cellares | Valuation | Koch Disruptive Technologies | |
| Apr, 2021 | Amount | Series B - Cellares | Valuation | Decheng Capital , Eclipse | |
| Aug, 2019 | Amount | Series A - Cellares | Valuation | Eclipse |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cellares
Cellares has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Bristol-Myers Squibb, Koch Disruptive Technologies and DFJ Growth. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by the venture capital firm.
|
Founded Year | Domain | Location | |
|
Investments are directed toward innovative technology startups by DFJ Growth.
|
Founded Year | Domain | Location | |
|
Philanthropic assets are managed by Willett Advisors LLC.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cellares
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cellares
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cellares Comparisons
Competitors of Cellares
Cellares operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Mission Bio, LUMICKS, LevitasBio and Rebus Biosystems, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Instrument systems for genomic research and sequencing libraries are developed.
|
|
| domain | founded_year | HQ Location |
Single-cell multi-omics platform is provided for genotypic and phenotypic analysis.
|
|
| domain | founded_year | HQ Location |
Optical tweezers instruments for single-molecule analysis are manufactured.
|
|
| domain | founded_year | HQ Location |
Single-cell imaging platform developed via magnetic levitation technology.
|
|
| domain | founded_year | HQ Location |
An imaging system for single-cell gene analysis is developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cellares
Frequently Asked Questions about Cellares
When was Cellares founded?
Cellares was founded in 2019.
Where is Cellares located?
Cellares is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Cellares?
Fabian Gerlinghaus is the current CEO of Cellares. They have also founded this company.
Is Cellares a funded company?
Cellares is a funded company, having raised a total of $355M across 3 funding rounds to date. The company's 1st funding round was a Series A of $18M, raised on Aug 01, 2019.
What does Cellares do?
Cellares was founded in 2019 and is based in San Francisco, United States. Operations focus on the biotechnology sector, where medical devices for cell-based therapy are manufactured. The Cell Shuttle platform is provided, integrating technologies for automated, end-to-end manufacturing processes with high throughput. A software suite supporting various cell therapy modalities is also offered to facilitate production workflows.
Who are the top competitors of Cellares?
Cellares's top competitors include 10X Genomics, Mission Bio and LUMICKS.
Who are Cellares's investors?
Cellares has 9 investors. Key investors include Bristol-Myers Squibb, Koch Disruptive Technologies, DFJ Growth, Willett Advisors, and Eclipse.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.